2025 | January monthly recap

2025 | January monthly recap


Editor's picks

Review the most promising opportunities from our online partnering platform, Connect, hand-picked by our team. Request an introduction connect with the asset owners, share feedback to guide their development, or follow the project to get notified of future updates. Sign up for the network here. ?


A new, safer viral vector platform

Biotech: Bio Design Lab

Researchers at Bio Design Lab have developed lentiviral and retroviral vectors with enhanced safety and efficiency, addressing challenges such as insertional mutagenesis and low transduction efficiency. Their vectors feature optimized components for improved safety, gene-loading capacity, and tissue targeting, enabling breakthroughs in cell therapies (CAR-T/NK) and gene therapies where AAVs fall short. The team are seeking partners for co-development and licensing.??

Read the full technology summary


Measuring CO2 in water to capture and sequester?

University: Science & Technologies Facilities Council

Researchers working at the Science & Technologies Facilities Council have developed a cutting-edge mid-infrared laser system that accurately measures carbon dioxide in water at injection well-heads for carbon capture and sequestration. Their real-time and cost-effective solution enhances transparency and efficiency in greenhouse gas monitoring, addressing challenges in industrial-scale emissions reduction. The team seeks a partner for co-development and licensing.?

Read the full technology summary?


New article

Top 25 innovations for 2025

This month, we released our annual list of top innovations set to have the biggest impact across science and R&D in the coming year. These are the opportunities that captured the most industry engagement on our partnering platform in 2024 - including smart contact lenses for measuring brain activity and a new CAR therapy for solid tumor cancers.

Read the full article


New report

Partnering 2030: Biopharma report?

Download our report to gain the view of over 250 responses from biotech companies and research institutes responding to our Partnering 2030 survey. The report includes a ranking of the top pharma companies, preferences for partnering, and the most and least successful partnering channels.???

Download the report for free??


Connect Campaigns

Connect Campaigns leverage our global scientific network to address industrial R&D needs and priorities through partnerships.?The campaigns below are active, seeking the submission of research, assets, expertise, and technologies from academic groups, TTOs, and startups.

??

Therapeutics for anxiety management

  • Company: Anonymous
  • Deadline for submissions: 21st February

A global health company is searching for therapeutics to address chronic and situational anxiety. They are particularly interested in treatments with rapid onset, suitable for either daily use (targeting 4-6 hours of efficacy) to manage situational anxiety or long-acting solutions (ideally monthly administration) for chronic anxiety.?

Read the full campaign brief


Biological and pharmacological interventions to treat and prevent obesity

  • Company: Novo Nordisk
  • Deadline for submissions: 10th March

The Transformational Prevention Unit at Novo Nordisk seeks innovative, multi-sector partnerships to develop scalable solutions that predict and prevent obesity, combining expertise across science, technology, and implementation for healthier, longer lives. They are open to pharmaceuticals, microbiome modulators, nutraceuticals, and medical devices.

Read the full campaign brief?


Manufacture of porous tubing

  • Company: Anonymous
  • Deadline for submissions: 12th March

A global leader in resource management is seeking partners developing innovative materials and processes for producing porous hollow tubing. The tubing must allow high water passage, withstand mechanical stress, remain flexible, and resist chemical degradation in challenging conditions.

Read the full campaign brief


Labiotech?

How the right clinical trial design software boosts success rates

The clinical development process is long, often exceeding ten years from discovery through regulatory approval. This article explores challenges in clinical trial design and show how choosing the right software solution can drastically improve the probability of clinical trial success.

Read the full article?



Inpart is the trusted platform for scientific partnering. We provide solutions to facilitate, optimize, and track collaborations helping bring science to life.

Our online partnering network is used by over 17,000 scientists and decision-makers in industry and academia matched by their research priorities and interests.

Signup for our network to identify new research and assets seeking partners, and establish new contacts for potential and future collaborations.

Or, speak with our team about how our platforms can help optimize your alliance management, due diligence, and partnering operations.

要查看或添加评论,请登录

Inpart的更多文章

社区洞察

其他会员也浏览了